Updates are available Correction dated 2024-02-21
Click to view Correction: https://doi.org/10.1038/s41586-024-07197-3
-
Authors
Amor, Corina http://orcid.org/0000-0002-7654-6216
Feucht, Judith
Leibold, Josef
Ho, Yu-Jui
Zhu, Changyu
Alonso-Curbelo, Direna
Mansilla-Soto, Jorge
Boyer, Jacob A.
Li, Xiang
Giavridis, Theodoros http://orcid.org/0000-0002-8716-781X
Kulick, Amanda
Houlihan, Shauna
Peerschke, Ellinor
Friedman, Scott L. http://orcid.org/0000-0003-1178-6195
Ponomarev, Vladimir
Piersigilli, Alessandra
Sadelain, Michel
Lowe, Scott W. http://orcid.org/0000-0002-5284-9650
- License Information
-
More Information
Article History
Received: 24 September 2019
Accepted: 6 May 2020
First Online: 17 June 2020
Change Date: 21 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07197-3
Competing interests
: A patent application (PCT/US2020/016290; filed on 02/01/2020) has been submitted based in part on results presented in this manuscript on the use of CAR T cells that target uPAR as senolytic agents. C.A., J.F., J.L., M.S. and S.W.L. are listed as the inventors. J.F. and M.S. hold other unrelated patents on CAR technologies.S.W.L. is an advisor for and has equity in the following biotechnology companies: ORIC Pharmaceuticals, Faeth Therapeutics, Blueprint Medicines, Geras Bio, Mirimus Inc., PMV Pharmaceuticals and Constellation Pharmaceuticals.
